- Title
- Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS
- Creators
- Paulos Gebrehiwet - Cytokinetics (United States)Lisa Meng - Cytokinetics (United States)Stacy A. Rudnicki - Cytokinetics (United States)Phil Sarocco - Cytokinetics (United States)Jenny Wei - Cytokinetics (United States)Andrew A. Wolff - Cytokinetics (United States)Michael Butzner - Cytokinetics (United States)Adriano Chiò - University of TurinJinsy A. Andrews - The Neurological InstituteAngela Genge - Montreal Neurological Institute and HospitalDyfrig A. Hughes - Bangor UniversityCarlayne E. Jackson - The University of Texas Health Science Center at San AntonioNoah Lechtzin - Johns Hopkins UniversityTimothy M. Miller - Washington University in St. LouisJeremy M. Shefner - Creighton University
- Publication Details
- Journal of medical economics, Vol.26(1), pp.488-493
- Number of pages
- 6
- Grant note
- Cytokinetics (http://data.elsevier.com/vocabulary/SciValFunders/100014941)
- Identifiers
- 991006262231202656
- Academic Unit
- Neurology
- Language
- English
- Resource Type
- Journal article
Journal article
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS
Journal of medical economics, Vol.26(1), pp.488-493
2023
PMID: 36930042
Metrics
1 Record Views